MedTrace Logo

Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.

NCT03539718 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-05-29

No results posted yet for this study

Summary

To assess the efficacy of Taurolock-hep500™ as anticoagulant and antimicrobial catheter lock solution in comparison to unfractionated heparin as alock solution to improve performance of hemodialysis catheters and quality of hemodialysis .

Conditions

  • Hemodialysis Catheter Infection
  • Thrombosis; Dialysis Catheter

Interventions

DRUG

Taurolidine heparin

Taurolock-hep 500 at end of session

DRUG

Heparin Sodium

Heparin sodium 5000 at end of session

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Magdy Sharkawy, MD · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-15
Primary Completion
2018-11-30
Completion
2019-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03539718 on ClinicalTrials.gov